<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chlorothiazide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chlorothiazide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chlorothiazide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9248" href="/d/html/9248.html" rel="external">see "Chlorothiazide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11599" href="/d/html/11599.html" rel="external">see "Chlorothiazide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F149881"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diuril;</li>
<li>Sodium Diuril [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057259"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Diuretic, Thiazide</span></li></ul></div>
<div class="block don drugH1Div" id="F53462404"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6125825-6207-4226-8e2b-6e9692dbb7a9">Edema, heart failure, bronchopulmonary dysplasia, hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis), heart failure, bronchopulmonary dysplasia, hypertension:</b> Limited data available; <b>Note:</b> Although the manufacturer states that IV and oral dosing are equivalent, some clinicians use lower IV doses due to poor oral absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 10 to 40 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-10693099','lexi-content-ref-6377221','lexi-content-ref-8176568','lexi-content-ref-21901679','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-10693099','lexi-content-ref-6377221','lexi-content-ref-8176568','lexi-content-ref-21901679','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Usual: 5 to 10 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Costello.1','lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Costello.1','lexi-content-ref-Eichenwald.1'])">Ref</a></span>); usual maximum daily dose: 12 mg/kg/day; doses up to 20 mg/kg/day have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31897073','lexi-content-ref-27834164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31897073','lexi-content-ref-27834164'])">Ref</a></span>). <b>Note:</b> Lower doses of 1 to 2 mg/kg/<b>dose</b> every 6 to 12 hours have effectively been used as adjunctive treatment with high-dose furosemide in postoperative management following cardiothoracic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31897073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31897073'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ef5f419-b63a-4776-a041-6dfb545e5ac2">Diabetes insipidus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus (central):</b> Limited data available: Oral: Initial: 10 mg/kg/day in 2 divided doses; may need to titrate dose to target urine osmolality: 100 to 150 mOsm/L; an effective dosing range of 5 to 10 mg/kg/<b>dose</b> twice or three times daily has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26130110','lexi-content-ref-17550208','lexi-content-ref-Sperling.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26130110','lexi-content-ref-17550208','lexi-content-ref-Sperling.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff97d538-3ef6-401e-ba61-af99d8a6f7a2">Hyperinsulinemia hypoglycemia, congenital hyperinsulinism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperinsulinemia hypoglycemia, congenital hyperinsulinism (adjunct therapy):</b> Limited data available: Oral: 7 to 10 mg/kg/day in 2 divided doses in combination with diazoxide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10685981','lexi-content-ref-14711860','lexi-content-ref-19193661','lexi-content-ref-33431709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10685981','lexi-content-ref-14711860','lexi-content-ref-19193661','lexi-content-ref-33431709'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F149902"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Although the manufacturer states that IV and oral dosing are equivalent; some clinicians use lower IV doses due to the poor oral absorption.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f56deae0-51c8-48a2-9917-c2ead3ff21ea">Edema, heart failure, hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis), heart failure, hypertension: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 10 to 40 mg/kg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-Ahlfeld.1','lexi-content-ref-7036914','lexi-content-ref-Rossano.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-Ahlfeld.1','lexi-content-ref-7036914','lexi-content-ref-Rossano.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum daily doses:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children &lt;2 years: Oral: 375 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥2 years: Oral: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: Oral: 2,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 5 to 10 mg/kg/day in divided doses once or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Costello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Costello.1'])">Ref</a></span>); doses up to 20 mg/kg/day have been described; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27834164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27834164'])">Ref</a></span>). <b>Note:</b> In infants &lt;6 months of age, lower doses of 1 to 2 mg/kg/<b>dose</b> every 6 to 12 hours have effectively been used as adjunctive treatment with high-dose furosemide in postoperative management following cardiothoracic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31897073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31897073'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ef5f419-b63a-4776-a041-6dfb545e5ac2">Diabetes insipidus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus (central):</b> Limited data available: Infants: Oral: Initial: 10 mg/kg/day in 2 divided doses; may need to titrate dose to target urine osmolality: 100 to 150 mOsm/L; an effective dosing range of 5 to 10 mg/kg/<b>dose</b> twice or three times daily has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26130110','lexi-content-ref-17550208','lexi-content-ref-Sperling.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26130110','lexi-content-ref-17550208','lexi-content-ref-Sperling.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084666"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Oral, IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment needed.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent</b>: Not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51084667"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F149885"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9248" href="/d/html/9248.html" rel="external">see "Chlorothiazide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65ef282d-23a6-4668-9e37-3d9d9236ddb8">Edema or general volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or general volume overload (adjunct to loop diuretic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimize loop diuretic therapy before adding chlorothiazide; combination diuretic therapy is typically for short-term use to restore euvolemia in patients already taking high-dose loop diuretic therapy who are resistant (eg, furosemide total daily dose of 160 to 320 mg/day IV or the oral equivalent). Combination diuretic therapy can cause severe electrolyte depletion (eg, potassium, magnesium, and sodium); prior to and during therapy, electrolytes should be monitored and appropriately repleted or managed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-21029871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-21029871'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV/Oral: </b>Usual dosage range: 250 mg to 1 g once or twice daily; maximum daily dose: 2 g/day; may administer every other day or on specific days of the week; may be administered in combination with or shortly before the scheduled loop diuretic. Assess volume status frequently (eg, daily or at least every 2 to 3 days) to determine effectiveness and to avoid over-diuresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-Brater.1','lexi-content-ref-Colucci.1','lexi-content-ref-21029871','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-Brater.1','lexi-content-ref-Colucci.1','lexi-content-ref-21029871','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>When a thiazide diuretic is chosen, chlorthalidone or indapamide is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>). For patients who warrant combination therapy (blood pressure ≥20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, dihydropyridine calcium channel blocker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). However, some experts prefer regimens that do not include thiazide diuretics for combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>: 500 mg to 1 g daily in 1 or 2 divided doses; may increase up to 2 g daily in 1 or 2 divided doses based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991609"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">CrCl &lt;10 mL/minute: Avoid use. Ineffective with CrCl &lt;30 mL/minute unless in combination with a loop diuretic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988837"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustments provided in manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F149843"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, necrotizing angiitis, orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness, headache, paresthesia, restlessness, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Glycosuria, hypercalcemia, hyperglycemia, hyperuricemia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hyponatremia, increased serum cholesterol, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (IV), impotence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, purpura, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm, systemic lupus erythematosus, weakness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, xanthopsia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis, renal failure, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis, pulmonary edema, respiratory distress</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Dermatologic: Psoriasis (Song 2021)</p></div>
<div class="block coi drugH1Div" id="F149860"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to chlorothiazide, any component of the formulation or sulfonamide-derived drugs; anuria</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p></div>
<div class="block war drugH1Div" id="F149840"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte disturbances: Hypercalcemia, hypokalemia, hypochloremic alkalosis, hyponatremia, and hypomagnesemia can occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: Concomitant ethanol use may increase the risk of orthostatic hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Photosensitization may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic kidney failure, gout can be precipitated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Avoid in severe kidney disease (ineffective). May precipitate azotemia; discontinue or consider withholding if kidney impairment occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: If given the morning of surgery, chlorothiazide may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F149853"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sodium Diuril: 500 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diuril: 250 mg/5 mL (237 mL) [contains alcohol, usp, benzoic acid, methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), saccharin sodium]</p></div>
<div class="block geq drugH1Div" id="F149836"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F149862"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Chlorothiazide Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $38.02 - $357.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Diuril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612402"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by direct IV infusion over 3 to 5 minutes or further dilute and infuse over 30 minutes. Avoid extravasation. Do <b>not</b> administer via IM or SUBQ route.</p></div>
<div class="block adm drugH1Div" id="F149857"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer slowly by direct IV injection or infusion; do <b>not</b> administer IM or SUBQ. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Shake suspension well before use.</p></div>
<div class="block sts drugH1Div" id="F149873"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Prior to reconstitution, store between 2°C to 25°C (36°F to 77°F). The manufacturer's labeling recommends any unused reconstituted solution be discarded. Precipitation will occur in &lt;24 hours in pH &lt;7.4.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store at room temperature 15°C to 30°C (59°F to 86°F). Protect from freezing.</p></div>
<div class="block usep drugH1Div" id="F53566004"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Suspension: Adjunctive treatment of edema due to heart failure, hepatic cirrhosis, and estrogen or corticosteroid therapy (FDA approved in pediatric patients [age not specified] and adults); treatment of edema due to various forms of renal dysfunction, including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure (FDA approved in pediatric patients [age not specified] and adults); management of hypertension either alone or in combination with other antihypertensive agents (FDA approved in pediatric patients [age not specified] and adults); has also been used for bronchopulmonary dysplasia (BPD), hyperinsulinemia hypoglycemia/congenital hyperinsulinism (adjunct therapy), and central diabetes insipidus of infancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Adjunctive treatment of edema due to heart failure, hepatic cirrhosis, and estrogen or corticosteroid therapy (FDA approved in adults); treatment of edema due to various forms of renal dysfunction including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure (FDA approved in adults); has also been used for BPD.</p></div>
<div class="block mst drugH1Div" id="F3196858"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics (chlorothiazide) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diuril [US] may be confused with Duorol brand name for acetaminophen [Spain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299022"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F149845"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Thiazide and Thiazide-Like Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May increase the serum concentration of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Arsenic Trioxide. Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. Management: Consider separating administraton of bile acid sequestrants and thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Calcium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Diazoxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide.  Management: Although hydrochlorothiazide is specifically cited as a contraindication, the risk likely extends to all thiazide and thiazide-like diuretics and may be even greater with chlorthalidone or bendroflumethiazide. Consider alternatives when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipragliflozin: May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Thiazide and Thiazide-Like Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Thiazide and Thiazide-Like Diuretics may decrease the excretion of Lithium.  Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Mecamylamine.  Management: Consider avoiding the use of mecamylamine and thiazide diuretics. If combined, mecamylamine prescribing information suggests reducing the mecamylamine dose by 50% in order to avoid excessive hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Methenamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the hypercalcemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Thiazide and Thiazide-Like Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F149865"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May need to decrease sodium and calcium, may need to increase potassium, zinc, magnesium, and riboflavin in diet. Some products may contain sodium.</p></div>
<div class="block rep_considerations drugH1Div" id="F58536604"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When diuretics are used for the treatment of heart failure in patients planning to become pregnant, adjust dose prior to conception to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F149863"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Chlorothiazide crosses the placenta and is found in cord blood. Maternal use may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults.</p>
<p style="text-indent:0em;margin-top:2em;">Use of thiazide diuretics during pregnancy may be considered to treat edema due to pathologic causes (as in the nonpregnant patient); monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small for gestational age, and increased risk of maternal and fetal death (Bright 2021). Thiazide diuretics may be used for symptom management in pregnant patients with heart failure complicated by pulmonary congestion; closely monitor volume status and adjust dose to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53566003"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes, urine output and renal function parameters, blood pressure, fluid balance (body weight).</p></div>
<div class="block pha drugH1Div" id="F149839"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits sodium and chloride reabsorption in the distal tubules causing increased excretion of sodium, chloride, and water resulting in diuresis. Loss of potassium, hydrogen ions, magnesium, phosphate, and bicarbonate also occurs.</p></div>
<div class="block phk drugH1Div" id="F149859"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Diuresis: Oral: Within 2 hours; IV: 15 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Oral: ~4 hours; IV: 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of diuretic action: Oral: ~6 to 12 hours; IV: 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Poor</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 45 to 120 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (10% to 15% [oral], 96% [IV] as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038559"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Saluric</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Chlotride</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Salutrid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diurilix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Saluric</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Chlotride</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Chlorzide | Chlotride | CTZ | Diurazide</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Chloorthiazide gf | Chloorthiazide MAE | Chloorthiazide ratiopharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Chlotride</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diuril</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Chlotride</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diurilix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Chlotride</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ahlfeld.1">
<a name="Ahlfeld.1"></a>Ahlfeld SK. Bronchopulmonary dysplasia. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 444.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26130110">
<a name="26130110"></a>Al Nofal A, Lteif A. Thiazide diuretics in the management of young children with central diabetes insipidus. <i>J Pediatr</i>. 2015;167(3):658-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/26130110/pubmed" id="26130110" target="_blank">26130110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479763">
<a name="12479763"></a>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)," <i>JAMA</i>, 2002, 288(23):2981-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/12479763/pubmed" id="12479763" target="_blank">12479763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10685981">
<a name="10685981"></a>Aynsley-Green A, Hussain K, Hall J, et al. Practical management of hyperinsulinism in infancy. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2000;82(2):F98-F107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/10685981/pubmed" id="10685981" target="_blank">10685981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338866">
<a name="27338866"></a>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2016;18(9):1096-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/27338866/pubmed" id="27338866" target="_blank">27338866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy. 2004;24(7):856-870.</i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol</i>. 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.1">
<a name="Brater.1"></a>Brater DC, Ellison DH. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259013">
<a name="34259013"></a>Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal Heart Failure. <i>J Am Heart Assoc</i>. 2021;10(14):e021019. doi:10.1161/JAHA.121.021019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/34259013/pubmed" id="34259013" target="_blank">34259013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31897073">
<a name="31897073"></a>Carpenter RJ, Kouyoumjian S, Moromisato DY, Lieu P, Amirnovin R. Lower-dose, intravenous chlorothiazide is an effective adjunct diuretic to furosemide following pediatric cardiac surgery. <i>J Pediatr Pharmacol Ther</i>. 2020;25(1):31-38. doi:10.5863/1551-6776-25.1.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/31897073/pubmed" id="31897073" target="_blank">31897073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Chlorothiazide for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” <i>JAMA</i>, 2003, 289(19):2560-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.1">
<a name="Colucci.1"></a>Colucci WS, Sterns RH. Use of diuretics in patients with heart failure. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Costello.1">
<a name="Costello.1"></a>Costello JM and Almodovar MC. Emergency care for infants and children with acute cardiac disease. <i>Clin Pediatr Emerg Med.</i> 2007;8(3):145-155.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salix.1">
<a name="Salix.1"></a>Diuril (chlorothiazide) oral suspension [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7036914">
<a name="7036914"></a>Hobbins SM, Fowler RS, Rowe RD, Korey AG. Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. <i>Arch Dis Child</i>. 1981;56(12):934-938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/7036914/pubmed" id="7036914" target="_blank">7036914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10693099">
<a name="10693099"></a>Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. <i>J Perinatol</i>. 2000;20(1):41-45. doi:10.1038/sj.jp.7200307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/10693099/pubmed" id="10693099" target="_blank">10693099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16160202">
<a name="16160202"></a>Hunt SA, Abraham WT, Chin MH, et al, "ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society," <i>Circulation</i>, 2005, 112(12):e154-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/16160202/pubmed" id="16160202" target="_blank">16160202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711860">
<a name="14711860"></a>Hussain K and Aynsley-Green A. Hyperinsulinaemic hypoglycaemia in preterm neonates. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2004;89(1):F65-F67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/14711860/pubmed" id="14711860" target="_blank">14711860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi: 10.1111/cen.12592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21029871">
<a name="21029871"></a>Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. <i>J Am Coll Cardiol</i>. 2010;56(19):1527-1534. doi:10.1016/j.jacc.2010.06.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/21029871/pubmed" id="21029871" target="_blank">21029871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8176568">
<a name="8176568"></a>Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. <i>J Pediatr</i>. 1994;124(5 Pt 1):772-781. doi:10.1016/s0022-3476(05)81373-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/8176568/pubmed" id="8176568" target="_blank">8176568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6377221">
<a name="6377221"></a>Kao LC, Warburton D, Cheng MH, Cedeño C, Platzker AC, Keens TG. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. <i>Pediatrics</i>. 1984;74(1):37-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/6377221/pubmed" id="6377221" target="_blank">6377221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193661">
<a name="19193661"></a>Kapoor RR, Flanagan SE, James C, et al. Hyperinsulinaemic hypoglycaemia. <i>Arch Dis Child</i>, 2009;94(6):450-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/19193661/pubmed" id="19193661" target="_blank">19193661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int</i>. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JF, Flack JF. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27834164">
<a name="27834164"></a>Moffett BS, Tsang R, Kennedy C, Bronicki RA, Akcan-Arikan A, Checchia PA. Efficacy of sequential nephron blockade with intravenous chlorothiazide to promote diuresis in cardiac intensive care infants. <i>Cardiol Young</i>. 2017;27(6):1104-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/27834164/pubmed" id="27834164" target="_blank">27834164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17550208">
<a name="17550208"></a>Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. <i>J Pediatr Endocrinol Metab</i>. 2007;20(4):459-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/17550208/pubmed" id="17550208" target="_blank">17550208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rossano.1">
<a name="Rossano.1"></a>Rossano JW. Heart failure. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 469.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8882303">
<a name="8882303"></a>Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. <i>Clin Pharmacokinet</i>. 1996;30(3):229-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/8882303/pubmed" id="8882303" target="_blank">8882303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33431709">
<a name="33431709"></a>Sotiridou E, Hoermann H, Aftab S, et al. Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1. <i>Endocrinol Diabetes Metab Case Rep</i>. Published online January 11, 2021. doi:10.1530/EDM-20-0174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/33431709/pubmed" id="33431709" target="_blank">33431709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21901679">
<a name="21901679"></a>Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. <i>Cochrane Database Syst Rev</i>. 2011;(9):CD001817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/21901679/pubmed" id="21901679" target="_blank">21901679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5074355">
<a name="5074355"></a>Werthmann MW Jr and Krees SV, "Excretion of Chlorothiazide in Human Breast Milk," <i>J Pediatr</i>, 1972, 81(4):781-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/5074355/pubmed" id="5074355" target="_blank">5074355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorothiazide-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13148 Version 298.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
